Johnson & Johnson Stock Falls 3.5% as Survey Finds Over 90% of Bladder Cancer Patients Report Severe Impacts
JNJ•A J&J-commissioned global survey of 817 NMIBC patients and 802 urologists across six countries finds over 90% of patients report moderate-to-severe physical, emotional and social impacts from radical cystectomy or BCG therapy. Separately, Johnson & Johnson shares have fallen 3.5% since its last earnings release 30 days ago, prompting investor reevaluation.
1. Comprehensive Patient Experience Survey
Johnson & Johnson collaborated with bladder cancer organizations to survey 817 non–muscle-invasive bladder cancer patients and 802 urologists in the US, Mexico, Brazil, Japan, Germany and France. More than 90% of patients undergoing radical cystectomy or BCG treatment reported negative physical, emotional and mental health impacts, with 76% describing treatment-related symptoms as humiliating and 94% missing important life moments due to therapy.
2. Unspoken Emotional and Quality-of-Life Burden
The survey revealed 86% of patients constantly worry about cancer recurrence, and 74% hide the emotional toll of their disease, with one in three always concealing how they feel. Over one-third of patients and nearly half of urologists cite minimizing life disruption as a top priority when choosing treatments, highlighting demand for more patient-centric options.
3. Recent Share Price Movement
In the 30 days following its latest earnings report, Johnson & Johnson shares have declined by 3.5%. This pullback may reflect investor concerns over pipeline innovation timelines and potential R&D spending needed to address patient demands for improved bladder cancer therapies.
